PODD: Buy at $234.09 Profit Taking at $292.61

٢٣ سبتمبر ٢٠٢٠

The diabetes market is ripe for innovation hence there is intense competition in the market. Some of the competitors are TNDM and DXCM, which both of great institutional sponsorship. The reason why PODD is up is due to the technical formation with a lower risk at a defined buy point. There is a consolidation base at the weekly chart and the daily chart is shaping up nicely although still with some 7% drops as shown. If it passes $234.09 with volume then it would be a great candidate to hold and observe the price action.

One of the great things about this company is that it is showing great earnings and has partnered up with DXCM to improve their product. Fundamentals are below

Sales:
Sep-19: +27%
Dec-19: +27%
Mar-20: +24%
Jun-20: +28%

Yearly EPS
2017: -0.46
2018: 0.05
2019: 0.19
2020: 0.36
2021: 1.23

٢ أكتوبر ٢٠٢٠

أغلقت الصفقة: تم الوصول لوقف الخسارة

Didn't breakout on volume and closed on the week below the buy price at 231.76. Overall 1% loss.